See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several types of inflammatory diseases, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation [1].

Regarding the effect of Cosentyx on post-vaccination immunity, there is limited research and information available. However, one study published in the Journal of Allergy and Clinical Immunology investigated the impact of IL-17 inhibitors, including secukinumab, on pneumococcal and tetanus vaccine responses in patients with psoriasis [2]. The study found that patients treated with IL-17 inhibitors had reduced antibody responses to both pneumococcal and tetanus vaccines compared to those not receiving these medications [2].

Another study published in the British Journal of Dermatology assessed the immunogenicity of the SARS-CoV-2 mRNA vaccine in patients with psoriasis receiving biologic therapies, including secukinumab [3]. The study found that patients on secukinumab had significantly lower antibody responses to the SARS-CoV-2 mRNA vaccine compared to those not receiving biologic therapies [3].

In summary, based on the available information, Cosentyx (secukinumab) may have a negative impact on post-vaccination immunity, particularly for pneumococcal, tetanus, and SARS-CoV-2 vaccines [2, 3]. However, more research is needed to fully understand the effect of Cosentyx on post-vaccination immunity. It is essential for healthcare providers and patients to discuss the potential implications of Cosentyx on vaccine responses when making treatment decisions.

Sources:

1. Drugs.com. Cosentyx. <https://www.drugs.com/cosentyx.html>
2. Gniadecki R, Reich A, Reich K, et al. Impaired antibody response to pneumococcal and tetanus vaccination in patients with psoriasis treated with interleukin-17 inhibitors. Journal of Allergy and Clinical Immunology. 2021;147(1):338-341.e3. <https://doi.org/10.1016/j.jaci.2020.09.013>
3. Kimball AB, Lebwohl M, Baddley JW, et al. Immunogenicity of SARS-CoV-2 mRNA vaccines in patients with psoriasis receiving biologic therapies. British Journal of Dermatology. 2021. <https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.20553>
4. DrugPatentWatch.com. Secukinumab. <https://www.drugpatentwatch.com/drugs/secukinumab>